Twenty years of dopamine research: Individual differences in the response of accumbal dopamine to environmental and pharmacological challenges

European Journal of Pharmacology

Volumn 585, Issue 2-3, 2008, Pages 228-244

  Verheij, Michel M M ^a   Cools, Alexander R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

(Apomorphine susceptible and unsusceptible rats); Alpha and beta adrenoceptors; Dopamine pool; High and low responders to novelty; Noradrenaline dopamine interaction; Norepinephrine dopamine interaction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE DERIVATIVE; COCAINE; DOPAMINE; DOPAMINE RECEPTOR; METHAMPHETAMINE; METHYLPHENIDATE; METIROSINE; PSYCHOSTIMULANT AGENT; RESERPINE; TETRABENAZINE; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER;

BINDING SITE; CATECHOLAMINE RELEASE; CATECHOLAMINE SYNTHESIS; DOPAMINE RELEASE; DRUG DEPENDENCE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RELEASE; DRUG RESEARCH; DRUG RESPONSE; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS; LOCOMOTION; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA;

ADRENERGIC UPTAKE INHIBITORS; ALPHA-METHYLTYROSINE; ANIMALS; BEHAVIOR; CATECHOLAMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE AGENTS; ENVIRONMENT; ENZYME INHIBITORS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INDIVIDUALITY; NOREPINEPHRINE; NUCLEUS ACCUMBENS; RECEPTORS, DOPAMINE; RESERPINE; SPACE PERCEPTION;

EID: 43049116111     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.084     Document Type: Review

References (302)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., and Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 155 (1998) 761-767
2. Ahlquist R.P. A study of the adrenotropic receptors. Am. J. Physiol. 153 (1948) 586-600
3. Ahlquist R.P. Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am. Heart J. 92 (1976) 661-664
4. Angrist B.M., Shopsin B., and Gershon S. Comparative psychotomimetic effects of stereoisomers of amphetamine. Nature 234 (1971) 152-153
5. Angrist B., Lee H.K., and Gershon S. The antagonism of amphetamine-induced symptomatology by a neuroleptic. Am. J. Psychiatry 131 (1974) 817-819
6. Angrist B., Rotrosen J., and Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology (Berl) 72 (1980) 17-19
7. Angrist B., Rotrosen J., and Gershon S. Commentary on: "Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia." Psychopharmacology (1980) 72:17-19. Psychopharmacology (Berl) 158 (2001) 219-221
8. Antelman S.M., and Caggiula A.R. Norepinephrine-dopamine interactions and behavior. Science 195 (1977) 646-653
9. Apps D.K., Pryde J.G., and Phillips J.H. Both the transmembrane pH gradient and the membrane potential are important in the accumulation of amines by resealed chromaffin-granule 'ghosts'. FEBS Lett. 111 (1980) 386-390
10. Arbuthnott G.W., Fairbrother I.S., and Butcher S.P. Dopamine release and metabolism in the rat striatum: an analysis by 'in vivo' brain microdialysis. Pharmacol. Ther. 48 (1990) 281-293
11. Augustine G.J., Charlton M.P., and Smith S.J. Calcium action in synaptic transmitter release. Annu. Rev. Neurosci. 10 (1987) 633-693
12. Baldo B.A., and Kelley A.E. Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacology (Berl) 191 (2007) 439-459
13. Bardo M.T., and Hammer Jr. R.P. Autoradiographic localization of dopamine D1 and D2 receptors in rat nucleus accumbens: resistance to differential rearing conditions. Neuroscience 45 (1991) 281-290
14. Beckstead R.M., Domesick V.B., and Nauta W.J. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res. 175 (1979) 191-217
15. Berger S.P., Winhusen T.M., Somoza E.C., Harrer J.M., Mezinskis J.P., Leiderman D.B., Montgomery M.A., Goldsmith R.J., Bloch D.A., Singal B.M., and Elkashef A. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 100 Suppl. 1 (2005) 58-67
16. Berridge K.C. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191 (2007) 391-431
17. Berridge C.W., and Morris M.F. Amphetamine-induced activation of forebrain EEG is prevented by noradrenergic beta-receptor blockade in the halothane-anesthetized rat. Psychopharmacology (Berl) 148 (2000) 307-313
18. Berridge C.W., Stratford T.L., Foote S.L., and Kelley A.E. Distribution of dopamine beta-hydroxylase-like immunoreactive fibers within the shell subregion of the nucleus accumbens. Synapse 27 (1997) 230-241
19. Besson M.J., Cheramy A., Feltz P., and Glowinski J. Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. Proc. Natl. Acad. Sci. U. S. A. 62 (1969) 741-748
20. Bevins R.A., Klebaur J.E., and Bardo M.T. Individual differences in response to novelty, amphetamine-induced activity and drug discrimination in rats. Behav. Pharmacol. 8 (1997) 113-123
21. Birnbaumer L. G proteins in signal transduction. Annu. Rev. Pharmacol. Toxicol. 30 (1990) 675-705
22. Birnbaumer L. Transduction of receptor signal into modulation of effector activity by G proteins: the first 20 years or so. FASEB J. 4 (1990) 3178-3188
23. Birnbaumer L., Abramowitz J., and Brown A.M. Receptor-effector coupling by G proteins. Biochim. Biophys. Acta 1031 (1990) 163-224
24. Braestrup C. Biochemical differentiation of amphetamine vs methylphenidate and nomifensine in rats. J. Pharm. Pharmacol. 29 (1977) 463-470
25. Brake W.G., Sullivan R.M., Flores G., Srivastava L.K., and Gratton A. Neonatal ventral hippocampal lesions attenuate the nucleus accumbens dopamine response to stress: an electrochemical study in the adult rat. Brain Res. 831 (1999) 25-32
26. Brog J.S., Salyapongse A., Deutch A.Y., and Zahm D.S. The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. J. Comp. Neurol. 338 (1993) 255-278
27. Budygin E.A., John C.E., Mateo Y., and Jones S.R. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice. J. Neurosci. 22 (2002) RC222
28. Budygin E.A., Brodie M.S., Sotnikova T.D., Mateo Y., John C.E., Cyr M., Gainetdinov R.R., and Jones S.R. Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 7781-7786
29. Buitelaar J.K., Michelson D., Danckaerts M., Gillberg C., Spencer T.J., Zuddas A., Faries D.E., Zhang S., and Biederman J. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol. Psychiatry 61 (2007) 694-699
30. Butcher S.P., Fairbrother I.S., Kelly J.S., and Arbuthnott G.W. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem. 50 (1988) 346-355
31. Butcher S.P., Liptrot J., and Aburthnott G.W. Characterisation of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis. Neurosci. Lett. 122 (1991) 245-248
32. Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., Molinoff P.B., Ruffolo Jr. R.R., and Trendelenburg U. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46 (1994) 121-136
33. Cadoni C., Pinna A., Russi G., Consolo S., and Di Chiara G. Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and Fos immunohistochemistry. Neuroscience 65 (1995) 1027-1039
34. Callaway C.W., Kuczenski R., and Segal D.S. Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res. 505 (1989) 83-90
35. Carboni E., Spielewoy C., Vacca C., Nosten-Bertrand M., Giros B., and Di Chiara G. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 21 (2001) RC141-RC144
36. Carelli R.M. The nucleus accumbens and reward: neurophysiological investigations in behaving animals. Behav. Cogn. Neurosci. Rev. 1 (2002) 281-296
37. Chefer V.I., Zakharova I., and Shippenberg T.S. Enhanced responsiveness to novelty and cocaine is associated with decreased basal dopamine uptake and release in the nucleus accumbens: quantitative microdialysis in rats under transient conditions. J. Neurosci. 23 (2003) 3076-3084
38. Chiueh C.C., and Moore K.E. d-amphetamine-induced release of "newly synthesized" and "stored" dopamine from the caudate nucleus in vivo. J. Pharmacol. Exp. Ther. 192 (1975) 642-653
39. Chopin P., Colpaert F.C., and Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 288 (1999) 798-804
40. Christenson J.G., Dairman W., and Udenfriend S. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic l-amino acid decarboxylase-serotonin-dopamine-norepinephrine). Proc. Natl. Acad. Sci. U. S. A. 69 (1972) 343-347
41. Clark D., and White F.J. D1 dopamine receptor: the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1 (1987) 347-388
42. Coccurello R., Adriani W., Oliverio A., and Mele A. Effect of intra-accumbens dopamine receptor agents on reactivity to spatial and non-spatial changes in mice. Psychopharmacology (Berl) 152 (2000) 189-199
43. Cole B.J., and Robbins T.W. Amphetamine impairs the discriminative performance of rats with dorsal noradrenergic bundle lesions on a 5-choice serial reaction time task: new evidence for central dopaminergic-noradrenergic interactions. Psychopharmacology (Berl) 91 (1987) 458-466
44. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26 (1987) 1431-1440
45. Colussi-Mas J., Panayi F., Scarna H., Renaud B., Berod A., and Lambas-Senas L. Blockade of beta-adrenergic receptors prevents amphetamine-induced behavioural sensitization in rats: a putative role of the bed nucleus of the stria terminalis. Int. J. Neuropsychopharmacol. 8 (2005) 569-581
46. Cools A.R. Two functionally and pharmacologically distinct dopamine receptors in the rat brain. Adv. Biochem. Psychopharmacol. 16 (1977) 215-225
47. Cools A.R. Clinical neuropharmacology of the basal ganglia. In: Vinken P.J., Bruyn G.W., and Klawans H.L. (Eds). Handbook of Clinical Neurology, Extrapyramidal Disorders (1986), Elsevier Science Publishers, Amsterdam 47-63
48. Cools A.R. Transformation of emotion into motion: role of mesolimbic noradrenaline and neostriatal dopamine. In: hellhammer D., Florin I., and Weiner H. (Eds). Neurobiological Approaches to Human Disease (1988), Hans Huber Publishers, Toronto 15-28
49. Cools A.R. Differential role of mineralocorticoid and glucocorticoid receptors in the genesis of dexamphetamine-induced sensitization of mesolimbic, alpha 1 adrenergic receptors in the ventral striatum. Neuroscience 43 (1991) 419-428
50. Cools A.R., and Ellenbroek B.A. Wistar rats: splitting high and low responders to novelty is necessary in basal ganglia research. In: Ohye C., and Kimura M. (Eds). The Basal Ganglia V (1996), Plenum Press, New York 493-498
51. Cools A.R., and Ellenbroek B.A. Animal models of personality. In: D'Haenen H.A.H., den Boer J.A., and Willner P. (Eds). Biological Psychiatry (2002), John Wiley & Sons, Ltd, London 1333-1344
52. Cools A.R., and Gingras M.A. Nijmegen high and low responders to novelty: a new tool in the search after the neurobiology of drug abuse liability. Pharmacol. Biochem. Behav. 60 (1998) 151-159
53. Cools A.R., and Oosterloo S.K. (3,4-Dihydroxyphenylimino)-2-imidazoline (DPI) and its action at noradrenergic and dopaminergic receptors in the nucleus accumbens of rats: mesolimbic catecholamine receptors and hyperactivity. J. Neural Transm., Suppl. 18 (1983) 181-188
54. Cools A.R., and Tuinstra T. Neurochemical evidence that mesolimbic noradrenaline directs mesolimbic dopamine, implying that noradrenaline, like dopamine, plays a key role in goal-directed and motivational behavior. In: Graybiel A.M., Delong M.R., and Kitai S.T. (Eds). The Basal Ganglia VI (Advances in Behavioral Biology, Volume 54) (2003), Plenum Publishers, New York 323-334
55. Cools A.R., and Van Rossum J.M. Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharmacologia. 45 (1976) 243-254
56. Cools A.R., and Van Rossum J.M. Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors. Life Sci. 27 (1980) 1237-1253
57. Cools A.R., and Verheij M.M.M. Alpha-adrenoceptors, but not beta-adrenoceptors, regulate the extracellular release of dopamine stored in reserpine-sensitive vesicular pools in the nucleus accumbens. Society for Neuroscience 32nd Annual Meeting, Orlando. Abstract Viewer and Itinerary Planner 2002 (2002) Program No. 736.3.2002.
58. Cools A.R., Ellenbroek B., Van den Bos R., and Gelissen M. Mesolimbic noradrenaline: specificity, stability and dose-dependency of individual-specific responses to mesolimbic injections of alpha-noradrenergic agonists. Behav. Brain Res. 25 (1987) 49-61
59. Cools A.R., Spooren W., Cuypers R., Bezemer R., and Jaspers R. Heterogeneous role of neostriatal and mesostriatal pathology in disorders of movement: a review and new facts. In: Crossman A.R., and Sambrook M.A. (Eds). Neural Mechanisms in Disorders of Movement (1989), John Libbey & company ltd., London 111-119
60. Cools A.R., Brachten R., Heeren D., Willemen A., and Ellenbroek B. Search after neurobiological profile of individual-specific features of Wistar rats. Brain Res. Bull. 24 (1990) 49-69
61. Cools A.R., Van den Bos R., Ploeger G., and Ellenbroek B.A. Gating function of noradrenaline in the ventral striatum: its role in behavioural responses to environmental and pharmacological challenges. In: Willner P., and Scheel-Kruger J. (Eds). The Mesolimbic Dopamine System: From Motivation to Action (1991), John Wiley & Sons, Chichester 141-173
62. Cools A.R., Ellenbroek B., Heeren D., and Lubbers L. Use of high and low responders to novelty in rat studies on the role of the ventral striatum in radial maze performance: effects of intra-accumbens injections of sulpiride. Can. J. Physiol. Pharm. 71 (1993) 335-342
63. Cools A.R., Rots N.Y., Ellenbroek B., and de Kloet E.R. Bimodal shape of individual variation in behavior of Wistar rats: the overall outcome of a fundamentally different make-up and reactivity of the brain, the endocrinological and the immunological system. Neuropsychobiology 28 (1993) 100-105
64. Cools A.R., Rots N.Y., de Kloet R., and Ellenbroek B. Apomorphine-susceptible and apomorphine-unsusceptible Wistar rats: a new tool in the search for the function of the striatum in switching behavioural strategies. In: Percheron G., McKenzie J.S., and Feger J. (Eds). The Basal Ganglia IV (1994), Plenum Press, New York 507-515
65. Cools A.R., Miwa Y., and Koshikawa N. Role of dopamine D1 and D2 receptors in the nucleus accumbens in jaw movements of rats: a critical role of the shell. Eur. J. Pharmacol. 286 (1995) 41-47
66. Cools A.R., Ellenbroek B.A., Gingras M.A., Engbersen A., and Heeren D. Differences in vulnerability and susceptibility to dexamphetamine in Nijmegen high and low responders to novelty: a dose-effect analysis of spatio-temporal programming of behaviour. Psychopharmacology (Berl) 132 (1997) 181-187
67. Cooper D.R., Marrel C., van de Waterbeemd H., Testa B., Jenner P., and Marsden C.D. l-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J. Pharm. Pharmacol. 39 (1987) 627-635
68. Costall B., and Naylor R.J. The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur. J. Pharmacol. 32 (1975) 87-92
69. Costall B., Naylor R.J., and Pinder R.M. Characterisation of the mechanisms for hyperactivity induction from the nucleus accumbens by phenylethylamine derivatives. Psychopharmacology (Berl) 48 (1976) 225-231
70. Crow T.J. Molecular pathology of schizophrenia: more than one disease process?. Br. Med. J. 280 (1980) 66-68
71. Davis M. Cocaine: excitatory effects on sensorimotor reactivity measured with acoustic startle. Psychopharmacology (Berl) 86 (1985) 31-36
72. Davis M., Svensson T.H., and Aghajanian G.K. Effects of d- and l-amphetamine on habituation and sensitization of the acoustic startle response in rats. Psychopharmacologia 43 (1975) 1-11
73. Delfs J.M., Zhu Y., Druhan J.P., and Aston-Jones G.S. Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res. 806 (1998) 127-140
74. Dellu F., Piazza P.V., Mayo W., Le Moal M., and Simon H. Novelty-seeking in rats: biobehavioral characteristics and possible relationship with the sensation-seeking trait in man. Neuropsychobiology 34 (1996) 136-145
75. Derome G., Tseng R., Mercier P., Lemaire I., and Lemaire S. Possible muscarinic regulation of catecholamine secretion mediated by cyclic GMP in isolated bovine adrenal chromaffin cells. Biochem. Pharmacol. 30 (1981) 855-860
76. Descarries L., Bosler O., Berthelet F., and Des-Rosiers M.H. Dopaminergic nerve endings visualised by high-resolution autoradiography in adult rat neostriatum. Nature 284 (1980) 620-622
77. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J. Neural Transm. Gen. Sect. 91 (1993) 197-221
78. Deutch A.Y., and Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46 (1992) 49-56
79. Di Chiara G., and Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr. Opin. Pharmacol. 7 (2007) 69-76
80. Di Chiara G., Loddo P., and Tanda G. Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression. Biol. Psychiatry 46 (1999) 1624-1633
81. DiLullo S.L., and Martin-Iverson M.T. Evidence for presynaptic dopamine mechanisms underlying amphetamine-conditioned locomotion. Brain Res. 578 (1992) 161-167
82. Drewett J.G., Ziegler R.J., Marchand G.R., and Trachte G.J. Cyclic guanosine 3′,5′ monophosphate mediates the inhibitory effect of atrial natriuretic factor in adrenergic, neuronal pheochromocytoma cells. J. Pharmacol. Exp. Ther. 250 (1989) 428-432
83. Duman R.S., Strada S.J., and Enna S.J. Effect of imipramine and adrenocorticotropin administration on the rat brain norepinephrine-coupled cyclic nucleotide generating system: alterations in alpha and beta adrenergic components. J. Pharmacol. Exp. Ther. 234 (1985) 409-414
84. Eccleston D., Fairbairn A.F., Hassanyeh F., McClelland H.A., and Stephens D.A. The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br. J. Psychiatry 147 (1985) 623-630
85. Einhorn L.C., Johansen P.A., and White F.J. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J. Neurosci. 8 (1988) 100-112
86. Ellenbroek B.A., and Cools A.R. Apomorphine susceptibility and animal models for psychopathology: genes and environment. Behav. Genet. 32 (2002) 349-361
87. Ellenbroek B.A., Van den Hoven J., and Cools A.R. The nucleus accumbens and forelimb muscular rigidity in rats. Exp.Brain Res. 72 (1988) 299-304
88. Ellenbroek B.A., Willemen A.P., and Cools A.R. Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology 2 (1989) 191-199
89. Ellenbroek B.A., Sluyter F., and Cools A.R. The role of genetic and early environmental factors in determining apomorphine susceptibility. Psychopharmacology (Berl) 148 (2000) 124-131
90. Erb S., Hitchcott P.K., Rajabi H., Mueller D., Shaham Y., and Stewart J. Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology 23 (2000) 138-150
91. Essman W.D., McGonigle P., and Lucki I. Anatomical differentiation within the nucleus accumbens of the locomotor stimulatory actions of selective dopamine agonists and d-amphetamine. Psychopharmacology (Berl) 112 (1993) 233-241
92. Estler C.J., and Ammon H.P. Modification by two beta-adrenergic blocking drugs of the effects of methamphetamine on behaviour and brain metabolism of mice. J. Neurochem. 18 (1971) 777-779
93. Everitt B.J., and Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8 (2005) 1481-1489
94. Ewing A.G., Bigelow J.C., and Wightman R.M. Direct in vivo monitoring of dopamine released from two striatal compartments in the rat. Science 221 (1983) 169-171
95. Finn I.B., Iuvone P.M., and Holtzman S.G. Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, d-amphetamine, and methylphenidate. Neuropharmacology 29 (1990) 625-631
96. Fischer J.F., and Cho A.K. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208 (1979) 203-209
97. Florin S.M., Kuczenski R., and Segal D.S. Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J. Pharmacol. Exp. Ther. 274 (1995) 231-241
98. Fuxe K., Goldstein M., Hokfelt T., Jonsson G., and Lidbrink P. Dopaminergic involvement in hypothalamic function: extrahypothalamic and hypothalamic control. A neuroanatomical analysis. Adv. Neurol. 5 (1974) 405-419
99. Garau L., Govoni S., Stefanini E., Trabucchi M., and Spano P.F. Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci. 23 (1978) 1745-1750
100. Garris P.A., Kilpatrick M., Bunin M.A., Michael D., Walker Q.D., and Wightman R.M. Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation. Nature 398 (1999) 67-69
101. George W.J., Polson J.B., O'Toole A.G., and Goldberg N.D. Elevation of guanosine 3′,5′-cyclic phosphate in rat heart after perfusion with acetylcholine. Proc. Natl. Acad. Sci. U. S. A. 66 (1970) 398-403
102. Gershanik O., Heikkila R.E., and Duvoisin R.C. Behavioral correlations of dopamine receptor activation. Neurology 33 (1983) 1489-1492
103. Gingras M.A., and Cools A.R. Differential ethanol intake in high and low responders to novelty. Behav. Pharmacol. 6 (1995) 718-723
104. Gingras M.A., and Cools A.R. No major differences in locomotor responses to dexamphetamine in high and low responders to novelty: a study in Wistar rats. Pharmacol. Biochem. Behav. 57 (1997) 857-862
105. Giorgi O., Corda M.G., Carboni G., Frau V., Valentini V., and Di Chiara G. Effects of cocaine and morphine in rats from two psychogenetically selected lines: a behavioral and brain dialysis study. Behav. Genet. 27 (1997) 537-546
106. Giorgi O., Lecca D., Piras G., Driscoll P., and Corda M.G. Dissociation between mesocortical dopamine release and fear-related behaviours in two psychogenetically selected lines of rats that differ in coping strategies to aversive conditions. Eur. J. Neurosci. 17 (2003) 2716-2726
107. Giorgi O., Piras G., Lecca D., and Corda M.G. Differential activation of dopamine release in the nucleus accumbens core and shell after acute or repeated amphetamine injections: a comparative study in the Roman high- and low-avoidance rat lines. Neuroscience 135 (2005) 987-998
108. Giorgi O., Piras G., and Corda M.G. The psychogenetically selected Roman high- and low-avoidance rat lines: a model to study the individual vulnerability to drug addiction. Neurosci. Biobehav. Rev. 31 (2007) 148-163
109. Goldstein M., Lauber E., and McKereghan M.R. Studies on the purification and characterization of 3,4-dihydroxyphenylethylamine beta-hydroxylase. J. Biol. Chem. 240 (1965) 2066-2072
110. Gorelick D.A., Gardner E.L., and Xi Z.X. Agents in development for the management of cocaine abuse. Drugs 64 (2004) 1547-1573
111. Grace A.A., Floresco S.B., Goto Y., and Lodge D.J. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci. 30 (2007) 220-227
112. Greengard P. Cyclic nucleotides, phosphorylated proteins, and the nervous system. Fed. Proc. 38 (1979) 2208-2217
113. Greenslade R.G., and Mitchell S.N. Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology 47 (2004) 1-8
114. Groenewegen H.J., Vermeulen-Van-der-Zee E., te-Kortschot A., and Witter M.P. Organization of the projections from the subiculum to the ventral striatum in the rat. A study using anterograde transport of Phaseolus vulgaris leucoagglutinin. Neuroscience 23 (1987) 103-120
115. Groenewegen H.J., Wright C.I., and Beijer A.V. The nucleus accumbens: gateway for limbic structures to reach the motor system?. Prog. Brain Res. 107 (1996) 485-511
116. Groenewegen H.J., Wright C.I., Beijer A.V., and Voorn P. Convergence and segregation of ventral striatal inputs and outputs. Ann. N. Y. Acad. Sci. 877 (1999) 49-63
117. Gross R.A., and Ferrendelli J.A. Relationships between norepinephrine and cyclic nucleotides in brain and seizure activity. Neuropharmacology 21 (1982) 655-661
118. Guerrero J.M., Reiter R.J., Poeggeler B., Chen L.D., and Tan D.X. Elevation of cyclic GMP levels in the rat pineal gland induced by nitric oxide. J. Pineal Res. 16 (1994) 210-214
119. Haapalinna A., Leino T., and Heinonen E. The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn-Schmiedebergs Arch. Pharmacol. 368 (2003) 342-351
120. Haber S.N. The primate basal ganglia: parallel and integrative networks. J. Chem. Neuroanat. 26 (2003) 317-330
121. Haber S.N., Fudge J.L., and McFarland N.R. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J. Neurosci. 20 (2000) 2369-2382
122. Haidamous M., Kouyoumdjian J.C., Briley P.A., and Gonnard P. In vivo effects of noradrenaline and noradrenergic receptor agonists and antagonists on rat cerebellar cyclic GMP levels. Eur. J. Pharmacol. 63 (1980) 287-294
123. Hanssen T., Heyden T., Sundberg I., Alfredsson G., Nyback H., and Wetterberg L. Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings. Arch. Gen. Psychiatry 37 (1980) 685-690
124. Hausdorff W.P., Caron M.G., and Lefkowitz R.J. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 4 (1990) 2881-2889
125. Hedou G., Feldon J., and Heidbreder C.A. Effects of cocaine on dopamine in subregions of the rat prefrontal cortex and their efferents to subterritories of the nucleus accumbens. Eur. J. Pharmacol. 372 (1999) 143-155
126. Heeringa M.J., and Abercrombie E.D. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J. Neurochem. 65 (1995) 192-200
127. Heidbreder C., and Feldon J. Amphetamine-induced neurochemical and locomotor responses are expressed differentially across the anteroposterior axis of the core and shell subterritories of the nucleus accumbens. Synapse 29 (1998) 310-322
128. Heikkila R.E., Orlansky H., and Cohen G. Studies on the distinction between uptake inhibition and release of (3H)dopamine in rat brain tissue slices. Biochem. Pharmacol. 24 (1975) 847-852
129. Heimer L., Zahm D.S., Churchill L., Kalivas P.W., and Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 41 (1991) 89-125
130. Henry J.P., Botton D., Sagne C., Isambert M.F., Desnos C., Blanchard V., Raisman-Vozari R., Krejci E., Massoulie J., and Gasnier B. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J. Exp. Biol. 196 (1994) 251-262
131. Henry J.P., Sagne C., Bedet C., and Gasnier B. The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem. Int. 32 (1998) 227-246
132. Hess S., Connamacher R., Ozaki M., and Udenfriend S. The effects of alpha-methyl-DOPA and alpha-methyl-metatyrosine on the metabolism of norepinephrine and serotonin in vivo. J. Pharmacol. Exp. Ther. 134 (1961) 129-138
133. Hiroi N., and White N.M. The reserpine-sensitive dopamine pool mediates (+)-amphetamine-conditioned reward in the place preference paradigm. Brain Res. 510 (1990) 33-42
134. Hooks M.S., Jones G.H., Smith A.D., Neill D.B., and Justice Jr. J.B. Response to novelty predicts the locomotor and nucleus accumbens dopamine response to cocaine. Synapse 9 (1991) 121-128
135. Hooks M.S., Colvin A.C., Juncos J.L., and Justice Jr. J.B. Individual differences in basal and cocaine-stimulated extracellular dopamine in the nucleus accumbens using quantitative microdialysis. Brain Res. 587 (1992) 306-312
136. Hooks M.S., Jones D.N., Holtzman S.G., Juncos J.L., Kalivas P.W., and Justice Jr. J.B. Individual differences in behavior following amphetamine, GBR-12909, or apomorphine but not SKF-38393 or quinpirole. Psychopharmacology (Berl) 116 (1994) 217-225
137. Hurd Y.L., and Ungerstedt U. Cocaine: an in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse 3 (1989) 48-54
138. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev. 56 (2007) 27-78
139. Ikemoto K., Kitahama K., Maeda T., and Satoh K. The distribution of noradrenaline, serotonin and gamma-aminobutyric acid in the monkey nucleus accumbens. Prog. Neuropsychopharmacol. Biol. Psychiatry 20 (1996) 1403-1412
140. Iyaniwura T.T., Wright A.E., and Balfour D.J. Evidence that mesoaccumbens dopamine and locomotor responses to nicotine in the rat are influenced by pretreatment dose and strain. Psychopharmacology (Berl) 158 (2001) 73-79
141. Jackson D.M., Anden N.E., and Dahlstrom A. A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain. Psychopharmacologia 45 (1975) 139-149
142. Jaiswal N., and Sharma R.K. Dual regulation of adenylate cyclase and guanylate cyclase: alpha 2-adrenergic signal transduction in adrenocortical carcinoma cells. Arch. Biochem. Biophys. 249 (1986) 616-619
143. Jarbe T.U. Cocaine as a discriminative cue in rats: interactions with neuroleptics and other drugs. Psychopharmacology (Berl) 59 (1978) 183-187
144. Javoy F., and Glowinski J. Dynamic characteristic of the 'functional compartment' of dopamine in dopaminergic terminals of the rat striatum. J. Neurochem. 18 (1971) 1305-1311
145. Jones S.R., O'Dell S.J., Marshall J.F., and Wightman R.M. Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain. Synapse 23 (1996) 224-231
146. Jones S.R., Gainetdinov R.R., Wightman R.M., and Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18 (1998) 1979-1986
147. Jongen-Relo A.L., Voorn P., and Groenewegen H.J. Immunohistochemical characterization of the shell and core territories of the nucleus accumbens in the rat. Eur. J. Neurosci. 6 (1994) 1255-1264
148. Justice Jr. J.B., Nicolaysen L.C., and Michael A.C. Modeling the dopaminergic nerve terminal. J. Neurosci.Methods 22 (1988) 239-252
149. Kabbaj M. Individual differences in vulnerability to drug abuse: the high responders/low responders model. CNS. Neurol. Disord. Drug Targets 5 (2006) 513-520
150. Kabbaj M., Devine D.P., Savage V.R., and Akil H. Neurobiological correlates of individual differences in novelty-seeking behavior in the rat: differential expression of stress-related molecules. J. Neurosci. 20 (2000) 6983-6988
151. Kabbaj M., Morley-Fletcher S., Le Moal M., and Maccari S. Individual differences in the effects of chronic prazosin hydrochloride treatment on hippocampal mineralocorticoid and glucocorticoid receptors. Eur. J. Neurosci. 25 (2007) 3312-3318
152. Kalivas P.W., Nemeroff C.B., and Prange Jr. A.J. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience 11 (1984) 919-930
153. Kanner B.I., Sharon I., Maron R., and Schuldiner S. Electrogenic transport of biogenic amines in chromaffin granule membrane vesicles. FEBS Lett. 111 (1980) 83-86
154. Katz B., and Miledi R. Ionic requirements of synaptic transmitter release. Nature 215 (1967) 651
155. Katz B., and Miledi R. Further study of the role of calcium in synaptic transmission. J. Physiol 207 (1970) 789-801
156. Kaufman S., and Friedman S. Dopamine-beta-hydroxylase. Pharmacol. Rev. 17 (1965) 71-100
157. Kebabian J.W., and Calne D.B. Multiple receptors for dopamine. Nature 277 (1979) 93-96
158. Kirouac G.J., and Ciriello J. Medullary inputs to nucleus accumbens neurons. Am. J. Physiol. 273 (1997) R2080-R2088
159. Kirshner N. Pathway of noradrenaline formation from DOPA. J. Biol. Chem. 226 (1957) 821-825
160. Kirshner N. Uptake of catecholamines by a particulate fraction of the adrenal medulla. Science 135 (1962) 107-108
161. Kirshner N., Rorie M., and Kamin D.L. Inhibition of dopamine uptake in vitro by reserpine administered in vivo. J. Pharmacol. Exp. Ther. 141 (1963) 285-289
162. Kobilka B. Adrenergic receptors as models for G protein-coupled receptors. Annu. Rev. Neurosci. 15 (1992) 87-114
163. Koene P., Prinssen E.P., and Cools A.R. Involvement of the nucleus accumbens in oral behaviour in the freely moving rat. Eur. J. Pharmacol. 233 (1993) 151-156
164. Koob G.F., and Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science 242 (1988) 715-723
165. Kuo J.F., Lee T.P., Reyes P.L., Walton K.G., Donnelly Jr. T.E., and Greengard P. Cyclic nucleotide-dependent protein kinases. X. An assay method for the measurement of quanosine 3′,5′-monophosphate in various biological materials and a study of agents regulating its levels in heart and brain. J. Biol. Chem. 247 (1972) 16-22
166. Laduron P., and Belpaire F. Tissue fractionation and catecholamines. II. Intracellular distribution patterns of tyrosine hydroxylase, dopa decarboxylase, dopamine-beta-hydroxylase, phenylethanolamine N-methyltransferase and monoamine oxidase in adrenal medulla. Biochem. Pharmacol. 17 (1968) 1127-1140
167. Lane E.L., Cheetham S., and Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J. Pharmacol. Exp. Ther. 312 (2005) 1124-1131
168. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9235-9240
169. Lategan A.J., Marien M.R., and Colpaert F.C. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 523 (1990) 134-138
170. Lecca D., Piras G., Driscoll P., Giorgi O., and Corda M.G. A differential activation of dopamine output in the shell and core of the nucleus accumbens is associated with the motor responses to addictive drugs: a brain dialysis study in Roman high- and low-avoidance rats. Neuropharmacology 46 (2004) 688-699
171. Lee T.P., Kuo J.F., and Greengard P. Role of muscarinic cholinergic receptors in regulation of guanosine 3′:5′-cyclic monophosphate content in mammalian brain, heart muscle, and intestinal smooth muscle. Proc. Natl. Acad. Sci. U. S. A. 69 (1972) 3287-3291
172. Lefkowitz R.J., Hausdorff W.P., and Caron M.G. Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends Pharmacol. Sci. 11 (1990) 190-194
173. Leviel V., Gobert A., and Guibert B. Direct observation of dopamine compartmentation in striatal nerve terminal by 'in vivo' measurement of the specific activity of released dopamine. Brain Res. 499 (1989) 205-213
174. Levin E., Levenberg B., and Kaufman S. The enzymatic conversion of 3,4-dihydroxyphenylethylamine to norepinephrine. J. Biol. Chem. 235 (1960) 2080-2086
175. Levitt M., Spector S., Sjoerdsma A., and Udenfriend S. Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea-pig heart. J. Pharmacol. Exp. Ther. 148 (1965) 1-8
176. Levitzki A. From epinephrine to cyclic AMP. Science 241 (1988) 800-806
177. Li Y.Q., Rao Z.R., and Shi J.W. Substance P-like immunoreactive neurons in the nucleus tractus solitarii of the rat send their axons to the nucleus accumbens. Neurosci. Lett. 120 (1990) 194-196
178. Liang C.L., Kozlowski G.P., Joseph S.A., and German D.C. ACTH1-39 inputs to mesocorticolimbic dopaminergic neurons: light and electron microscopic examination. Neurosci. Lett. 146 (1992) 79-83
179. Liang N.Y., and Rutledge C.O. Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem. Pharmacol. 31 (1982) 983-992
180. Lim N.F., Nowycky M.C., and Bookman R.J. Direct measurement of exocytosis and calcium currents in single vertebrate nerve terminals. Nature 344 (1990) 449-451
181. Lindstrom L.H., and Persson E. Propranolol in chronic schizophrenia: a controlled study in neuroleptic-treated patients. Br. J. Psychiatry 137 (1980) 126-130
182. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G.G., Eisenberg D., Brecha N., and Edwards R.H. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70 (1992) 539-551
183. Lovenberg W., Weissbach H., and Udenfriend S. Aromatic l-amino acid decarboxylase. J. Biol. Chem. 237 (1962) 89-93
184. Lucas L.R., Angulo J.A., Le Moal M., McEwen B.S., and Piazza P.V. Neurochemical characterization of individual vulnerability to addictive drugs in rats. Eur. J. Neurosci. 10 (1998) 3153-3163
185. Mantegazza P., Naimzada K.M., and Riva M. Effects of propranolol on some activities of amphetamine. Eur. J. Pharmacol. 4 (1968) 25-30
186. Marchi M., Paudice P., Gemignani A., and Raiteri M. Is the muscarinic receptor that mediates potentiation of dopamine release negatively coupled to the cyclic GMP system? J. Neurosci. Res. 17 (1987) 142-145
187. Martin-Iverson M.T., Yamada N., By A.W., and Lodge B.A. "Designer" amphetamines: effects on behavior and monoamines with or without reserpine and/or alpha-methyl-para-tyrosine pretreatment. J. Psychiatry Neurosci. 16 (1991) 253-261
188. Mateo Y., Budygin E.A., John C.E., Banks M.L., and Jones S.R. Voltammetric assessment of dopamine clearance in the absence of the dopamine transporter: no contribution of other transporters in core or shell of nucleus accumbens. J. Neurosci. Methods 140 (2004) 183-187
189. Mavridis M., Colpaert F.C., and Millan M.J. Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists. Brain Res. 562 (1991) 216-224
190. McKittrick C.R., and Abercrombie E.D. Catecholamine mapping within nucleus accumbens: differences in basal and amphetamine-stimulated efflux of norepinephrine and dopamine in shell and core. J. Neurochem. 100 (2007) 1247-1256
191. McMillen B.A. CNS stimulants: two distinct mechanisms of action for amphetamine-like drugs. Trends Pharmacol. Sci. 4 (1983) 429-432
192. McMillen B.A., German D.C., and Shore P.A. Functional and pharmacological significance of brain dopamine and norepinephrine storage pools. Biochem. Pharmacol. 29 (1980) 3045-3050
193. Mele A., Avena M., Roullet P., De Leonibus E., Mandillo S., Sargolini F., Coccurello R., and Oliverio A. Nucleus accumbens dopamine receptors in the consolidation of spatial memory. Behav. Pharmacol. 15 (2004) 423-431
194. Mercuri N.B., Calabresi P., and Bernardi G. The mechanism of amphetamine-induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording in vitro. Br. J. Pharmacol. 98 (1989) 127-134
195. Mitchell J.B., and Gratton A. Involvement of mesolimbic dopamine neurons in sexual behaviors: implications for the neurobiology of motivation. Rev. Neurosci. 5 (1994) 317-329
196. Mobley P.L., and Sulser F. Adrenal corticoids regulate sensitivity of noradrenaline receptor-coupled adenylate cyclase in brain. Nature 286 (1980) 608-609
197. Mogenson G.J., Jones D.L., and Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Prog. Neurobiol. 14 (1980) 69-97
198. Morgane P.J., Galler J.R., and Mokler D.J. A review of systems and networks of the limbic forebrain/limbic midbrain. Prog. Neurobiol. 75 (2005) 143-160
199. Musacchio J.M. Subcellular distribution of adrenal tyrosine hydroxylase. Biochem. Pharmacol. 17 (1968) 1470-1473
200. Nagatsu T., Levitt M., and Udenfriend S. Conversion of l-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues. Biochem. Biophys. Res. Commun. 14 (1964) 543-549
201. Nagatsu T., Levitt M., and Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J. Biol. Chem. 239 (1964) 2910-2917
202. Niddam R., Arbilla S., Scatton B., Dennis T., and Langer S.Z. Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine. Naunyn-Schmiedebergs Arch. Pharmacol. 329 (1985) 123-127
203. Nirenberg M.J., Chan J., Pohorille A., Vaughan R.A., Uhl G.R., Kuhar M.J., and Pickel V.M. The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J. Neurosci. 17 (1997) 6899-6907
204. Nurse B., Russell V.A., and Taljaard J.J. Alpha 2 and beta-adrenoceptor agonists modulate [3H]dopamine release from rat nucleus accumbens slices: implications for research into depression. Neurochem. Res. 9 (1984) 1231-1238
205. Nurse B., Russell V.A., and Taljaard J.J. Effect of chronic desipramine treatment on adrenoceptor modulation of [3H]dopamine release from rat nucleus accumbens slices. Brain Res. 334 (1985) 235-242
206. O'Donohue T.L., Crowley W.R., and Jacobowitz D.M. Biochemical mapping of the noradrenergic ventral bundle projection sites: evidence for a noradrenergic-dopaminergic interaction. Brain Res. 172 (1979) 87-100
207. Oka M., Kajikawa K., Ohuchi T., Yoshida H., and Imaizumi R. Distribution of dopamine-beta-hydroxylase in subcellular fractions of adrenal medulla. Life Sci. 6 (1967) 461-465
208. Olson L., Seiger A., and Fuxe K. Heterogeneity of striatal and limbic dopamine innervation: highly fluorescent islands in developing and adult rats. Brain Res. 44 (1972) 283-288
209. Parker E.M., and Cubeddu L.X. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores. J. Pharmacol. Exp. Ther. 237 (1986) 179-192
210. Pelayo F., Dubocovich M.L., and Langer S.Z. Possible role of cyclic nucleotides in regulation of noradrenaline release from rat pineal through presynaptic adrenoceptors. Nature 274 (1978) 76-78
211. Pennartz C.M., Groenewegen H.J., and Lopes-da-Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog. Neurobiol. 42 (1994) 719-761
212. Perchellet J.P., and Sharma R.K. Ectopic alpha-adrenergic mediated accumulation of guanosine 3′,5′-monophosphate in isolated adrenocortical carcinoma cells. Endocrinology 106 (1980) 1589-1593
213. Peter D., Liu Y., Sternini C., de Giorgio R., Brecha N., and Edwards R.H. Differential expression of two vesicular monoamine transporters. J. Neurosci. 15 (1995) 6179-6188
214. Piazza P.V., Deminiere J.M., Le Moal M., and Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science 245 (1989) 1511-1513
215. Piazza P.V., Maccari S., Deminiere J.M., Le Moal M., Mormede P., and Simon H. Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 2088-2092
216. Piazza P.V., Rouge-Pont F., Deroche V., Maccari S., Simon H., and Le Moal M. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8716-8720
217. Pifl C., Drobny H., Reither H., Hornykiewicz O., and Singer E.A. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47 (1995) 368-373
218. Pijnenburg A.J., and Van Rossum J.M. Letter: Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens. J. Pharm. Pharmacol. 25 (1973) 1003-1005
219. Pijnenburg A.J., Honig W.M., and Van Rossum J.M. Effects of antagonists upon locomotor stimulation induced by injection of dopamine and noradrenaline into the nucleus accumbens of nialamide-pretreated rats. Psychopharmacologia 41 (1975) 175-180
220. Plaznik A., Danysz W., and Kostowski W. A stimulatory effect of intraaccumbens injections of noradrenaline on the behavior of rats in the forced swim test. Psychopharmacology (Berl) 87 (1985) 119-123
221. Plaznik A., Stefanski R., and Kostowski W. Interaction between accumbens D1 and D2 receptors regulating rat locomotor activity. Psychopharmacology (Berl) 99 (1989) 558-562
222. Ploeger G.E., Willemen A.P., and Cools A.R. Role of the nucleus accumbens in social memory in rats. Brain Res. Bull. 26 (1991) 23-27
223. Ploeger G.E., Spruijt B.M., and Cools A.R. Spatial localization in the Morris water maze in rats: acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol. Behav. Neurosci. 108 (1994) 927-934
224. Pontieri F.E., Tanda G., and Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 12304-12308
225. Prinssen E.P., Balestra W., Bemelmans F.F., and Cools A.R. Evidence for a role of the shell of the nucleus accumbens in oral behavior of freely moving rats. J. Neurosci. 14 (1994) 1555-1562
226. Pugh C.R., Steinert J., and Priest R.G. Propranolol in schizophrenia: a double blind, placebo controlled trial of propranolol as an adjunct to neuroleptic medication. Br. J. Psychiatry 143 (1983) 151-155
227. Raiteri M., Cerrito F., Cervoni A.M., and Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther. 208 (1979) 195-202
228. Rocha B.A., Fumagalli F., Gainetdinov R.R., Jones S.R., Ator R., Giros B., Miller G.W., and Caron M.G. Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci. 1 (1998) 132-137
229. Roozendaal B., and Cools A.R. Influence of the noradrenergic state of the nucleus accumbens in basolateral amygdala mediated changes in neophobia of rats. Behav. Neurosci. 108 (1994) 1107-1118
230. Rots N.Y., Cools A.R., de Jong J., and de Kloet E.R. Corticosteroid feedback resistance in rats genetically selected for increased dopamine responsiveness. J. Neuroendocrinol. 7 (1995) 153-161
231. Rots N.Y., Cools A.R., Oitzl M.S., de Jong J., Sutanto W., and de Kloet E.R. Divergent prolactin and pituitary-adrenal activity in rats selectively bred for different dopamine responsiveness. Endocrinology 137 (1996) 1678-1686
232. Rouge-Pont F., Piazza P.V., Kharouby M., Le Moal M., and Simon H. Higher and longer stress-induced increase in dopamine concentrations in the nucleus accumbens of animals predisposed to amphetamine self-administration. A microdialysis study. Brain Res. 602 (1993) 169-174
233. Rouge-Pont F., Deroche V., Le Moal M., and Piazza P.V. Individual differences in stress-induced dopamine release in the nucleus accumbens are influenced by corticosterone. Eur. J. Neurosci. 10 (1998) 3903-3907
234. Russell V.A., Lamm M.C., and Taljaard J.J. Effect of ethanol on [3H]dopamine release in rat nucleus accumbens and striatal slices. Neurochem. Res. 13 (1988) 487-492
235. Russell V.A., Lamm M.C., Allin R., de Villiers A.S., Searson A., and Taljaard J.J. Effect of selective noradrenergic denervation on noradrenaline content and [3H]dopamine release in rat nucleus accumbens slices. Neurochem. Res. 14 (1989) 169-172
236. Russell V.A., Lamm M.C., and Taljaard J.J. Lack of interaction between alpha 2-adrenoceptors and dopamine D2-receptors in mediating their inhibitory effects on [3H]dopamine release from rat nucleus accumbens slices. Neurochem. Res. 18 (1993) 285-289
237. Sabol K.E., and Seiden L.S. Reserpine attenuates d-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res. 806 (1998) 69-78
238. Saigusa T., Tuinstra T., Koshikawa N., and Cools A.R. High and low responders to novelty: effects of a catecholamine synthesis inhibitor on novelty-induced changes in behaviour and release of accumbal dopamine. Neuroscience 88 (1999) 1153-1163
239. Salamone J.D. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav. Brain Res. 61 (1994) 117-133
240. Salamone J.D., Correa M., Mingote S.M., and Weber S.M. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr. Opin. Pharmacol. 5 (2005) 34-41
241. Scheel-Kruger J. Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain. Eur. J. Pharmacol. 14 (1971) 47-59
242. Scheel-Kruger J. Behavioural and biochemical comparison of amphetamine derivatives, cocaine, benztropine and tricyclic anti-depressant drugs. Eur. J. Pharmacol. 18 (1972) 63-73
243. Scheel-Kruger J., Braestrup C., Nielson M., Golembiowska K., and Mogilnicka E. Cocaine: discussion on the role of dopamine in the biochemical mechanism of action. In: Ellinwood Jr. E.H., and Kilbey M.M. (Eds). Advances in Behavioral Biology (1977), Plenum press, New York 373-407
244. Schoemaker H., and Nickolson V.J. Dopamine uptake by rat striatal synaptosomes: a compartmental analysis. J. Neurochem. 41 (1983) 684-690
245. Schoffelmeer A.N., Wardeh G., and Mulder A.H. Cyclic AMP facilitates the electrically evoked release of radiolabelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices. Naunyn-Schmiedebergs Arch. Pharmacol. 330 (1985) 74-76
246. Schultz W. Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. Curr. Opin. Neurobiol. 14 (2004) 139-147
247. Seeman P., and Van Tol H.H. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15 (1994) 264-270
248. Sethi B.B., and Dube S. Propranolol in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 7 (1983) 89-99
249. Setlow B., and McGaugh J.L. Sulpiride infused into the nucleus accumbens posttraining impairs memory of spatial water maze training. Behav. Neurosci. 112 (1998) 603-610
250. Sharpe L.G., Pilotte N.S., Mitchell W.M., and De Souza E.B. Withdrawal of repeated cocaine decreases autoradiographic [3H]mazindol-labelling of dopamine transporter in rat nucleus accumbens. Eur. J. Pharmacol. 203 (1991) 141-144
251. Shilliam C.S., and Heidbreder C.A. Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens. Eur. J. Pharmacol. 477 (2003) 113-122
252. Sjoerdsma A., Engelman K., Spector S., and Udenfriend S. Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet 2 (1965) 1092-1094
253. Sluyter F., Hof M., Ellenbroek B.A., Degen S.B., and Cools A.R. Genetic, sex, and early environmental effects on the voluntary alcohol intake in Wistar rats. Pharmacol. Biochem. Behav. 67 (2000) 801-808
254. Smith D.G., Tzavara E.T., Shaw J., Luecke S., Wade M., Davis R., Salhoff C., Nomikos G.G., and Gehlert D.R. Mesolimbic dopamine super-sensitivity in melanin-concentrating hormone-1 receptor-deficient mice. J. Neurosci. 25 (2005) 914-922
255. Sora I., Wichems C., Takahashi N., Li X.F., Zeng Z., Revay R., Lesch K.P., Murphy D.L., and Uhl G.R. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7699-7704
256. Spector S., Sjoerdsma A., and Udenfriend S. Blockade of endogenous norepinephrine synthesis by alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J. Pharmacol. Exp. Ther. 147 (1965) 86-95
257. Srinivasan J., and Schmidt W.J. Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence. Behav. Brain Res. 154 (2004) 353-363
258. Stoof J.C., and Kebabian J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294 (1981) 366-368
259. Struyker-Boudier H.A., and Cools A.R. (3,4-Dihydroxyphenylimino)-2-imidazoline (DPI): a stimulant of alpha-adrenoceptors and dopamine receptors. J. Pharm. Pharmacol. 36 (1984) 859-860
260. Sulzer D., Maidment N.T., and Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60 (1993) 527-535
261. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., and Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15 (1995) 4102-4108
262. Sulzer D., St Remy C., and Rayport S. Reserpine inhibits amphetamine action in ventral midbrain culture. Mol. Pharmacol. 49 (1996) 338-342
263. Sutanto W., de Kloet E.R., de Bree F., and Cools A.R. Differential corticosteroid binding characteristics to the mineralocorticoid (type 1) and glucocortocoid (type 2) receptors in the brain of the pharmacogenetically selected apomorphine susceptible and apomorphine-unsusceptibile Wistar rats. Neurosci. Res. Commun. 5 (1989) 19-26
264. Sutton M.A., and Beninger R.J. Psychopharmacology of conditioned reward: evidence for a rewarding signal at D1-like dopamine receptors. Psychopharmacology (Berl) 144 (1999) 95-110
265. Svensson A., Carlsson M.L., and Carlsson A. Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice. J. Neural Transm. Gen. Sect. 101 (1995) 127-148
266. Swanson C.J., Heath S., Stratford T.R., and Kelley A.E. Differential behavioral responses to dopaminergic stimulation of nucleus accumbens subregions in the rat. Pharmacol. Biochem. Behav. 58 (1997) 933-945
267. Titeler M., Weinreich P., Sinclair D., and Seeman P. Multiple receptors for brain dopamine. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 1153-1156
268. Tremblay M., Rouillard C., and Levesque D. Dopamine D3 receptor antisense administration reduces basal c-fos and NGFI-B mRNA levels in the rat forebrain. Synapse 32 (1999) 51-57
269. Tuinstra T., and Cools A.R. High and low responders to novelty: effects of adrenergic agents on the regulation of accumbal dopamine under challenged and non-challenged conditions. Neuroscience 99 (2000) 55-64
270. Tuinstra T., and Cools A.R. Newly synthesized dopamine in the nucleus accumbens is regulated by beta-adrenergic, but not alpha-adrenergic, receptors. Neuroscience 98 (2000) 743-747
271. Tuinstra T., Verheij M., Willemen A., Iking J., Heeren D.J., and Cools A.R. Retrieval of spatial information in Nijmegen high and low responders: involvement of beta-adrenergic mechanisms in the nucleus accumbens. Behav. Neurosci. 114 (2000) 1088-1095
272. Tuinstra T., Cobelens P., Lubbers L., Verheij M., and Cools A.R. High and low responders to novelty and mesolimbic noradrenaline: effects of noradrenergic agents on radial-maze performance. Behav. Neurosci. 116 (2002) 1084-1092
273. Unemoto H., Sasa M., and Takaori S. A noradrenaline-induced inhibition from locus coeruleus of nucleus accumbens neuron receiving input from hippocampus. Jpn. J. Pharmacol. 39 (1985) 233-239
274. Unemoto H., Sasa M., and Takaori S. Inhibition from locus coeruleus of nucleus accumbens neurons activated by hippocampal stimulation. Brain Res. 338 (1985) 376-379
275. Van den Bos R., Charria-Ortiz G.A., Bergmans A.C., and Cools A.R. Evidence that dopamine in the nucleus accumbens is involved in the ability of rats to switch to cue-directed behaviours. Behav. Brain Res. 42 (1991) 107-114
276. van der Elst M.C., Roubos E.W., Ellenbroek B.A., Veening J.G., and Cools A.R. Apomorphine-susceptible rats and apomorphine-unsusceptible rats differ in the tyrosine hydroxylase-immunoreactive network in the nucleus accumbens core and shell. Exp. Brain Res. 160 (2005) 418-423
277. van der Elst M.C., Verheij M.M., Roubos E.W., Ellenbroek B.A., Veening J.G., and Cools A.R. A single exposure to novelty differentially affects the accumbal dopaminergic system of apomorphine-susceptible and apomorphine-unsusceptible rats. Life Sci. 76 (2005) 1391-1406
278. van der Kam E.L., Coolen J.C., Ellenbroek B.A., and Cools A.R. The effects of stress on alcohol consumption: mild acute and sub-chronic stressors differentially affect apomorphine susceptible and unsusceptible rats. Life Sci. 76 (2005) 1759-1770
279. van Dongen Y.C., Deniau J.M., Pennartz C.M., Galis-de-Graaf Y., Voorn P., Thierry A.M., and Groenewegen H.J. Anatomical evidence for direct connections between the shell and core subregions of the rat nucleus accumbens. Neuroscience 136 (2005) 1049-1071
280. Verheij M.M., and Cools A.R. Differential contribution of storage pools to the extracellular amount of accumbal dopamine in high and low responders to novelty: effects of reserpine. J. Neurochem. 100 (2007) 810-821
281. Verheij, M.M., De Mulder, E.L., De Leonibus, E., Van Loo, K.M., Cools, A.R., in press. Rats that differentially respond to cocaine differ in their dopaminergic storage capacity of the nucleus accumbens. J. Neurochem. doi:10.1111/j.1471-4159.2008.05323.x.
282. Volle R.L., and Quenzer L.F. Regulation of cyclic GMP levels in nerve tissue. Fed. Proc. 42 (1983) 3099-3102
283. Volosin M., Cancela L.M., and Molina V.A. ACTH accelerates the attenuation of alpha 2-adrenoceptors response in nucleus accumbens following chronic desipramine. Methods Find. Exp. Clin. Pharmacol. 14 (1992) 189-192
284. Wallukat G. The beta-adrenergic receptors. Herz 27 (2002) 683-690
285. Watanabe S., Aono Y., Fusa K., Takada K., Saigusa T., Koshikawa N., and Cools A.R. Contribution of vesicular and cytosolic dopamine to the increased striatal dopamine efflux elicited by intrastriatal injection of dexamphetamine. Neuroscience 136 (2005) 251-257
286. Weihe E., Schafer M.K., Erickson J.D., and Eiden L.E. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J. Mol. Neurosci. 5 (1994) 149-164
287. Weiner N. Multiple factors regulating the release of norepinephrine consequent to nerve stimulation. Fed. Proc. 38 (1979) 2193-2202
288. Westerink B.H., Tuntler J., Damsma G., Rollema H., and de Vries J.B. The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn-Schmiedebergs Arch. Pharmacol. 336 (1987) 502-507
289. Westerink R.H. Targeting exocytosis: ins and outs of the modulation of quantal dopamine release. CNS Neurol. Disord. Drug Targets 5 (2006) 57-77
290. Westfall T.C., Kitay D., and Wahl G. The effect of cyclic nucleotides on the release of 3H-dopamine from rat striatal slices. J. Pharmacol. Exp. Ther. 199 (1976) 149-157
291. Wieczorek W., and Kruk Z.L. Influences of neuronal uptake and D2 autoreceptors on regulation of extracellular dopamine in the core, shell and rostral pole of the rat nucleus accumbens. Brain Res. 699 (1995) 171-182
292. Wightman R.M., Heien M.L., Wassum K.M., Sombers L.A., Aragona B.J., Khan A.S., Ariansen J.L., Cheer J.F., Phillips P.E., and Carelli R.M. Dopamine release is heterogeneous within microenvironments of the rat nucleus accumbens. Eur. J. Neurosci. 26 (2007) 2046-2054
293. Wright C.I., Beijer A.V., and Groenewegen H.J. Basal amygdaloid complex afferents to the rat nucleus accumbens are compartmentally organized. J. Neurosci. 16 (1996) 1877-1893
294. Wurzburger R.J., and Musacchio J.M. Subcellular distribution and aggregation of bovine adrenal tyrosine hydroxylase. J. Pharmacol. Exp. Ther. 177 (1971) 155-168
295. Yan Q.S. Involvement of non-exocytotic mechanisms in ethanol-induced in vivo dopamine release: comparisons with cocaine. Eur. J. Pharmacol. 477 (2003) 37-44
296. Yaroslavsky I., Colletti M., Jiao X., and Tejani-Butt S. Strain differences in the distribution of dopamine (DA-2 and DA-3) receptor sites in rat brain. Life Sci. 79 (2006) 772-776
297. Yorkston N.J., Zaki S.A., Pitcher D.R., Gruzelier J.H., Hollander D., and Sergeant H.G. Propranolol as an adjunct to the treatment of schizophrenia. Lancet 2 (1977) 575-578
298. Zagon A., Totterdell S., and Jones R.S. Direct projections from the ventrolateral medulla oblongata to the limbic forebrain: anterograde and retrograde tract-tracing studies in the rat. J. Comp. Neurol. 340 (1994) 445-468
299. Zahm D.S. Functional-anatomical implications of the nucleus accumbens core and shell subterritories. Ann. N.Y. Acad. Sci. 877 (1999) 113-128
300. Zahm D.S. An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci. Biobehav. Rev. 24 (2000) 85-105
301. Zahm D.S., and Brog J.S. On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience 50 (1992) 751-767
302. Zhou J. Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 29 (2004) 1235-1244